People diagnosed with cancer over a year ago and those who were not on treatment did not have a higher risk of hospitalization or death.

CoVac-1 induced T-cell responses in about 90% of immunocompromised people with impaired B-cell function.

The new—and free—computational tool, CoSpar, integrates two sources of data about a cell.

Protecting the immunocompromised is not only a matter of health equity, it’s critical to ending the pandemic.

Some people undergoing cancer treatment do not respond well to COVID-19 vaccines, leaving them at risk for severe illness.

Transplant recipients, people with advanced HIV and certain people with cancer or autoimmune diseases can get an additional vaccine dose.

People with cancer not only are at increased risk for severe COVID-19, they also face treatment interruptions due to the pandemic.

98% of people who received the customized immunotherapy responded to the one-time treatment.

Removing naive T cells before a stem cell transplant in certain cancer patients may prevent chronic graft-versus-host disease.

The first two people treated with the “living drug” remained cancer-free for a decade and can be considered cured.